Summary
Acute Heart Failure (AHF) is a sudden worsening of the signs and symptoms of chronic heart failure, which typically includes
difficulty in breathing, leg or feet swelling and fatigue. HF is a growing global problem, affecting millions of people around the
world (present in 1%-12% in Europe and the United States. The lifetime risk of developing the disease ranging in between
20%-33%). AHF is the most common cause of hospitalization for patients older than 65 years of age. Over the last 3
decades, the hospitalization rates for patients with AHF has tripled and is expected to increase. An ageing population will
increase the prevalence of AHF, which in turn will lead to significant monetary expenses. Fluid decongestion is the key
treatment of AHF, where 90% of patients are treated with diuretics. However, 30%-40% of patients are resistant to diuretics.
The DorayaTM is the first device to directly create an optimal hemodynamic environment, enabling diuretic efficiency to
relieve congestion and restore organ function. The DorayaTM catheter regulates vascular hemodynamics in AHF patients,
including those who have developed diuretic resistance. Chronic Heart Failure market is expected to increase from €2.64bn
in 2015 to €8.78bn in 2025, which represents a 12.9% of CAGR. Since, AHF market accounts for 75% of the total Chronic
Heart Failure market, the total available global market by 2025 is expected to reach €6.59bn. With 30% of patients resistant
to diuretics, this represents a huge unmet market that Doraya can service.
difficulty in breathing, leg or feet swelling and fatigue. HF is a growing global problem, affecting millions of people around the
world (present in 1%-12% in Europe and the United States. The lifetime risk of developing the disease ranging in between
20%-33%). AHF is the most common cause of hospitalization for patients older than 65 years of age. Over the last 3
decades, the hospitalization rates for patients with AHF has tripled and is expected to increase. An ageing population will
increase the prevalence of AHF, which in turn will lead to significant monetary expenses. Fluid decongestion is the key
treatment of AHF, where 90% of patients are treated with diuretics. However, 30%-40% of patients are resistant to diuretics.
The DorayaTM is the first device to directly create an optimal hemodynamic environment, enabling diuretic efficiency to
relieve congestion and restore organ function. The DorayaTM catheter regulates vascular hemodynamics in AHF patients,
including those who have developed diuretic resistance. Chronic Heart Failure market is expected to increase from €2.64bn
in 2015 to €8.78bn in 2025, which represents a 12.9% of CAGR. Since, AHF market accounts for 75% of the total Chronic
Heart Failure market, the total available global market by 2025 is expected to reach €6.59bn. With 30% of patients resistant
to diuretics, this represents a huge unmet market that Doraya can service.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/855362 |
| Start date: | 01-01-2019 |
| End date: | 30-04-2019 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Acute Heart Failure (AHF) is a sudden worsening of the signs and symptoms of chronic heart failure, which typically includesdifficulty in breathing, leg or feet swelling and fatigue. HF is a growing global problem, affecting millions of people around the
world (present in 1%-12% in Europe and the United States. The lifetime risk of developing the disease ranging in between
20%-33%). AHF is the most common cause of hospitalization for patients older than 65 years of age. Over the last 3
decades, the hospitalization rates for patients with AHF has tripled and is expected to increase. An ageing population will
increase the prevalence of AHF, which in turn will lead to significant monetary expenses. Fluid decongestion is the key
treatment of AHF, where 90% of patients are treated with diuretics. However, 30%-40% of patients are resistant to diuretics.
The DorayaTM is the first device to directly create an optimal hemodynamic environment, enabling diuretic efficiency to
relieve congestion and restore organ function. The DorayaTM catheter regulates vascular hemodynamics in AHF patients,
including those who have developed diuretic resistance. Chronic Heart Failure market is expected to increase from €2.64bn
in 2015 to €8.78bn in 2025, which represents a 12.9% of CAGR. Since, AHF market accounts for 75% of the total Chronic
Heart Failure market, the total available global market by 2025 is expected to reach €6.59bn. With 30% of patients resistant
to diuretics, this represents a huge unmet market that Doraya can service.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
